Progyny 3rd Quarter 2026 Earnings Conference Call - PROGYNY INC

Financial Performance:

• Third-quarter revenue exceeded the midpoint of guidance, reflecting a nearly 9% year-over-year increase; full-year organic revenue growth (excluding a former client) is projected at 10.1% to 11.7%.
• Gross margins expanded by 130 basis points to a record level, driven by scale efficiencies in care management and reduced stock-based compensation.
• Adjusted EBITDA margins remained consistent at 17.1% on a trailing 12-month basis, despite increased investment; adjusted EBITDA for the quarter exceeded expectations.
• Operating cash flow generation remained robust at $56 million for the quarter and $207 million trailing 12-months, maintaining a >75% conversion rate from adjusted EBITDA for seven consecutive quarters.
• Working capital stood at $224 million, including $196 million in cash and equivalents; the company has $0 debt, no outstanding borrowings against its $200 million revolving credit facility, and a DSO of 66 days (down 7 days YoY).
• Share repurchases totaled $83 million in Q3 (approx. 3 million shares), bringing the cumulative total to over 14 million shares (nearly 15% reduction in outstanding shares) since November.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $1.365–$1.385 billion; adjusted EBITDA guidance raised to $235–$240 million; net income guidance raised to $107–$110.6 million.
• Full-year 2026 adjusted EPS guidance raised to $1.30–$1.35; Q4 2026 revenue guidance set at $344.7–$364.6 million (8.3%–14.6% growth); Q4 adjusted EBITDA guidance set at $57.9–$62.9 million.
• Management projects a 2027 operating base of over 660 clients and 8.3 million covered lives, with the majority of the recent 1.3 million new lives launching in Q1 2027.
• Investment levels are expected to taper throughout 2027, positioning the company for incremental margin expansion as integration and platform build-out costs normalize.
• Q4 engagement metrics are trending higher to normal seasonal patterns, with strong visibility through October and November supporting guidance.

Business Segments and Product Lines:

• The most recent selling season delivered record results with 1.3 million new covered lives and over 85 new clients, including major universities, tech leaders, and a large US bank.
• Retention of the existing client base remained near 100%, with approximately 20% of the base expanding their service footprint (consolidating women's health services) for 2027.
• "Progeny Select" (fully insured market offering) was an immaterial contributor this year as the company focused on infrastructure and relationships; it is expected to scale as a key long-term growth driver.
• Pharmacy program (Progeny Rx) achieved a near 100% attach rate among new business and is projected to cover 95–96% of total clients by 2027, with over 3 million lives covered in expanded products.
• New client acquisition was broad-based across geographies and industries, with no single client or sector representing an outsized portion of the book.

Market and Competitive Landscape:

• Strong macro demand for fertility and women's health benefits is driven by rising medical costs, workforce retention needs, and the prevalence of infertility (1 in 5).
• Competitive rationalization is evident, with one competitor exiting and another downsizing, indicating capital flow toward proven models like Progeny's.
• Progeny reported competitive takeaways, though these were not the primary driver of success; wins were attributed to differentiated solutions, cost containment track records, and member outcomes.
• The partnership with Cigna remains a strategic channel, though specific new learnings from the first season were described as consistent with existing consulting partner dynamics.
• Management notes that large employer competitors are facing challenges, creating active conversations, though Progeny emphasizes a diversified pipeline rather than reliance on any single large account.

Risks and Challenges:

• Utilization rates may fluctuate due to seasonality and treatment timing (e.g., ART cycle intensity), though current trends are within expected ranges.
• Medical cost inflation and GLP-1 drug costs continue to pressure client budgets, requiring Progeny to demonstrate superior cost control to maintain value propositions.
• Forward-looking statements carry risks regarding demand, selling season timing, client decision-making, and employment levels in served industries.
• A slight Q3 utilization increase was noted but attributed to normal seasonality and deferred care seeking, with no material deviation from long-term models.

Management Commentary and Tone:

• Management tone was highly confident and optimistic, citing a "strong quarter," "record revenue," and the strongest sales momentum ever for the upcoming 2027 season.
• CEO Peter Nevsky emphasized the differentiation of their solution in a cost-inflationary environment, highlighting the alignment of employer priorities (cost control + member experience) with Progeny's outcomes.
• CFO Mark Livingston highlighted disciplined financial management, consistent cash conversion, and the ability to expand margins while funding growth initiatives.
• Management reiterated that while competition exists, the market is rationalizing around proven efficacy, and Progeny is well-positioned with its largest-ever pipeline and diverse client base.

Analyst Questions and Answers:

• Utilization Economics: Confirming that large public sector clients (e.g., CalPERS) are underwritten with slightly lower utilization expectations to maintain consistent margin profiles.
• Margin Trajectory: Confirmed that investment tapering in 2027 should support incremental margin expansion, though formal 2027 guidance will be provided in February.
• Competitive Landscape: Addressed whether large employer challenges are driving business; confirmed active conversations but emphasized that overall sales growth is driven by broad strategy execution rather than just competitor takeaways.
• Q4 Guidance: Explained the sequential Q4 revenue bump as a return to normal seasonal activity following a slower Q3, with strong visibility into October and November.
• Expansion Trends: Noted that 20% of existing clients are expanding services, consistent with historical upsell rates, and expanded product attach rates are positive.
• Cigna Partnership: Reiterated that partner-led sales follow standard consulting partner dynamics and that eligibility file collection is on track to cover >50% of lives by year-end.
• Margin Composition: Clarified that gross margin expansion was driven by operational efficiencies and the phasing out of stock-based comp, while SG&A saw year-over-year investment in GTM resources and platform expansion.

Other Key Points:

• The 1.3 million new lives added this season are roughly balanced between "brownfield" (upgrading existing partial benefits) and "greenfield" (new comprehensive benefits), with utilization expected to be consistent with the broader book.
• Membership size remained essentially flat quarter-over-quarter, with minor fluctuations attributed to administrative updates rather than trends.
• Progeny Select is expected to become a key growth pillar but remains in the early infrastructure-building phase, with immaterial revenue impact for 2026.
• The company has no planned use of its $200 million credit facility and prioritizes share repurchases and organic investment for capital allocation.